• Restore CFTR FunctionCompleted with Results

  Phase 1 exploratory study on the effect of the drug QR-010 on nasal cells , protocol number ProQR PQ-010-002

  This study evaluated the effectiveness of the drug eluforsen (when sprayed in the nose) to improve nasal cell chloride transport. This study was for people with CF who have at least one copy of the F508del CFTR mutation.

  • Age:

    18 Years and Older

  • Mutation(s):

    Two Copies F508del or One Copy F508del

  • FEV1% Predicted:

    40% or greater

  • Number of Visits:

    8

  • Length of Participation:

    7 weeks

• Restore CFTR FunctionCompleted with Results

  Phase 1b safety study of QR-010 in adults with CF , protocol number ProQR PQ-010-001

  This study evaluated the safety and tolerability of the inhaled drug eluforsen in people with CF who have two copies of the F508del CFTR mutation.

  • Age:

    18 Years to 60 Years

  • Mutation(s):

    Two Copies F508del

  • FEV1% Predicted:

    70% or greater

  • Number of Visits:

    10

  • Length of Participation:

    8 weeks

Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.